The American company Novavax has announced that its Nuvaxovid vaccine will be launched in France at the beginning of February. A very special vaccine because it does not contain messenger RNA like all other vaccines.
After Pfizer/BioNTech, AstraZeneca, Moderna, Sputnik, the President of the European Commission Ursula Von der Leyen authorises the administration of Novavax’s anti-Covid vaccine in the EU. One more vaccine to fight this Covid-19 virus that shakes the world. But is it really necessary at a time when a new variant, Omicron, has appeared, many scientists think that the pandemic is slowly coming to an end.
Ian Jones, a virologist at the University of Reading, points out that recent UK data “show that a person affected by the Omicron variant appears to be between 50% and 70% less likely to be hospitalised”. So, although this variant is more contagious, it also appears to be less dangerous than the Delta variant. For this reason, some scientists even predict herd immunity within months.
On the other hand, because of the different mutations of the virus, we can expect a new variant in the spring, “We are therefore not safe from a bad surprise, even if we think that the next mutants will probably be more contaminating and less virulent”, explains Yves Coppieters, professor of public health at the Université libre de Belgique.
This new vaccine developed by the Novavax laboratory is a “recombinant subunit” vaccine. The process of this vaccine differs from other vaccines already available on the market. The principle is to inject into the body a protein that resembles the “Spike protein” of the virus, which then triggers the production of antibodies against the real S protein of the Coronavirus.
Despite promising results from tests on mice, it is still too early to say whether this latest vaccine is really necessary to combat Covid-19.